MA47041A1 - Composition liquide de suspension de smectite et son procédé de préparation - Google Patents

Composition liquide de suspension de smectite et son procédé de préparation

Info

Publication number
MA47041A1
MA47041A1 MA47041A MA47041A MA47041A1 MA 47041 A1 MA47041 A1 MA 47041A1 MA 47041 A MA47041 A MA 47041A MA 47041 A MA47041 A MA 47041A MA 47041 A1 MA47041 A1 MA 47041A1
Authority
MA
Morocco
Prior art keywords
liquid
preparation
suspension liquid
present
suspension
Prior art date
Application number
MA47041A
Other languages
English (en)
Other versions
MA47041B1 (fr
Inventor
Ye Chang
Qing Ri Li
Sang Ho Seol
Tie Li
Chao Tong
Original Assignee
Dae Woong Pharma
Liaoning Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma, Liaoning Daewoong Pharmaceutical Co Ltd filed Critical Dae Woong Pharma
Publication of MA47041A1 publication Critical patent/MA47041A1/fr
Publication of MA47041B1 publication Critical patent/MA47041B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Colloid Chemistry (AREA)

Abstract

La présente invention concerne un liquide de suspension comprenant de la smectite. Le liquide de suspension de la présente invention présente d’excellents dispersibilité et taux de sédimentation dans le liquide de suspension au moyen d’un agent de suspension à poids moléculaire élevé et d’un agent de suspension de poids moléculaire faible, et la viscosité d’une forme pharmaceutique n’est pas élevée et est ainsi facile à prendre, présente une observance médicamenteuse élevée lorsqu’elle est prise et présente une palatabilité élevée. De plus, le liquide de suspension de la présente invention permet une dispersion uniforme pendant la préparation et permet ainsi une préparation facile et efficace. Par conséquent, le taux de défaut pendant la fabrication d’une formulation liquide en suspension peut être réduit.
MA47041A 2017-04-13 2018-04-12 Composition liquide de suspension de smectite et son procédé de préparation MA47041B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710240595.1A CN108721325B (zh) 2017-04-13 2017-04-13 蒙脱石混悬液及其制备方法
PCT/KR2018/004304 WO2018190658A1 (fr) 2017-04-13 2018-04-12 Composition liquide de suspension de smectite et son procédé de préparation

Publications (2)

Publication Number Publication Date
MA47041A1 true MA47041A1 (fr) 2020-04-30
MA47041B1 MA47041B1 (fr) 2020-12-31

Family

ID=63793726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47041A MA47041B1 (fr) 2017-04-13 2018-04-12 Composition liquide de suspension de smectite et son procédé de préparation

Country Status (16)

Country Link
US (1) US20200046762A1 (fr)
EP (1) EP3610858A4 (fr)
KR (1) KR102396351B1 (fr)
CN (2) CN108721325B (fr)
BR (1) BR112019021427A2 (fr)
CA (1) CA3058879A1 (fr)
CO (1) CO2019012428A2 (fr)
EA (1) EA038764B1 (fr)
MA (1) MA47041B1 (fr)
MX (1) MX2019012085A (fr)
MY (1) MY202378A (fr)
PH (1) PH12019502322A1 (fr)
SA (1) SA519410274B1 (fr)
TN (1) TN2019000276A1 (fr)
WO (1) WO2018190658A1 (fr)
ZA (1) ZA201906661B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972418B (zh) * 2021-05-18 2021-08-27 北京金城泰尔制药有限公司 硝呋太尔制霉素阴道软胶囊及其制备方法
CN116077437A (zh) * 2022-12-29 2023-05-09 合肥久诺医药科技有限公司 一种蒙脱石混悬剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512345D0 (en) * 1985-05-15 1985-06-19 Scras Anti-diarrhea compositions
US5238881A (en) * 1988-11-09 1993-08-24 Engelhard Corporation Stable color dispersions, their preparation and use in ceramic glazes
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
AU2003210812A1 (en) * 2002-02-04 2003-09-02 Pharmacia Corporation Stable pharmaceutical composition useful for treating gastrointestinal disorders
EP1677755A4 (fr) * 2003-10-28 2011-12-28 Taro Pharmaceuticals Usa Inc Formulations base d'argiles r sistantes au d bordement
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
CN101112387B (zh) * 2007-08-06 2011-04-13 南京白敬宇制药有限责任公司 一种治疗非感染性腹泻的蒙脱石混悬液及其制备方法
CN101129326A (zh) * 2007-08-15 2008-02-27 济南康众医药科技开发有限公司 一种蒙脱石混悬剂制备方法
EP2228054A1 (fr) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Suspensions aqueuses au riluzole
EP2386289A1 (fr) * 2010-04-29 2011-11-16 Ipsen Pharma S.A.S. Compositions d'argile
CN102218078B (zh) * 2011-04-19 2012-10-10 南京威泰珐玛兽药研究所有限公司 一种含有蒙脱石的利福昔明混悬液及其制备方法
US9486460B2 (en) * 2014-04-29 2016-11-08 The Procter & Gamble Company Bismuth containing liquid pharmaceutical suspensions
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
CN106265724A (zh) * 2015-06-08 2017-01-04 四川健能制药有限公司 蒙脱石混悬液
CN107198679A (zh) * 2015-07-09 2017-09-26 河南蓝图制药有限公司 一种蒙脱石微丸干混悬剂及其制备方法
CN106606476A (zh) * 2015-10-27 2017-05-03 康芝药业股份有限公司 一种布洛芬混悬滴剂及其制备方法
CN106281044B (zh) * 2016-08-09 2018-10-30 西安博尔新材料有限责任公司 一种悬浮型水性研磨液的制备方法

Also Published As

Publication number Publication date
EA201992353A1 (ru) 2020-03-03
PH12019502322A1 (en) 2020-07-06
CN109414407A (zh) 2019-03-01
BR112019021427A2 (pt) 2020-05-05
CO2019012428A2 (es) 2020-01-17
EP3610858A4 (fr) 2020-09-02
SA519410274B1 (ar) 2022-06-05
MX2019012085A (es) 2020-01-20
ZA201906661B (en) 2020-08-26
KR20190130589A (ko) 2019-11-22
KR102396351B1 (ko) 2022-05-10
TN2019000276A1 (en) 2021-05-07
MY202378A (en) 2024-04-24
EA038764B1 (ru) 2021-10-15
CA3058879A1 (fr) 2018-10-18
CN109414407B (zh) 2020-08-25
MA47041B1 (fr) 2020-12-31
CN108721325B (zh) 2020-03-06
US20200046762A1 (en) 2020-02-13
WO2018190658A1 (fr) 2018-10-18
EP3610858A1 (fr) 2020-02-19
CN108721325A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
CN1158994C (zh) 含环丙沙星和地塞米松的局部悬浮制剂
MA47041A1 (fr) Composition liquide de suspension de smectite et son procédé de préparation
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
JP2012511009A (ja) 薬学的懸濁物
AU2014251532B2 (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
EP2364692A3 (fr) Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
FR3097564B1 (fr) Procede de preparation de nanoparticules d’or pentamaclees a haute concentration
Shaker et al. In-situ injectable thermosensitive gel based on poloxamer as a new carrier for tamoxifen citrate
WO2021262916A8 (fr) Formulations pharmaceutiques de griséofulvine pour administration oculaire à long terme
CN1158995C (zh) 氟米龙眼用混悬液
JP2017088629A (ja) 二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物
JP5740906B2 (ja) 眼科用剤
JP2015034142A (ja) プレフィルドシリンジ製剤
JP2015172043A (ja) ナルフラフィン塩酸塩を含有するカプセル製剤
FR3113609B1 (fr) Fabrication d’un aérogel à gradient de conduction électrique
JP2006143590A (ja) 粘膜適用組成物
FR3103817B1 (fr) Composition comprenant un polymère à étapes multiples et un polymère (méth)acrylique, son procédé de préparation et son utilisation
JP2006111621A (ja) ピレノキシン懸濁型点眼剤
JP6571391B2 (ja) 水性製剤
JP2008031165A (ja) ビタミンａ類を含有する水性組成物
MA40599A1 (fr) Formulations injectables de paracétamol
JP5854077B2 (ja) 経口摂取用ゲル状組成物、及びその製造方法
CN103796653A (zh) 抑制水性液剂粘度降低的方法
EP4106726A1 (fr) Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l'amitriptyline